Voitheia Bioscience Raised $7M+

We’re proud to back Voitheia Bioscience — a company redefining what’s possible in the treatment of neurodegenerative disease.

While most neurology drugs focus on slowing decline…
Voitheia is focused on restoring what’s been lost.

Their approach centers on remyelination — repairing the brain’s wiring so function can actually come back.
Not management.
Restoration.

That’s a fundamental shift in how these diseases are treated.

And the momentum is real 👇

• $7M+ raised to date (grants + venture capital)
• Backed by leading institutions including CDMRP & the U.S. Department of Defense
• Advancing toward mid-stage clinical trials for their remyelination platform
• Built on 15+ years of R&D and breakthrough academic research
• Supported by granted patents + a strong proprietary moat
• Led by an all-female team pushing the frontier of bioscience

Under the hood, Voitheia is building a full-stack platform:
→ A potent remyelination therapeutic
→ Companion diagnostics
→ Precision biomarkers

All designed to shift neurology from slowing disease → restoring function at scale.

The market already exists.
The need is urgent.

No one has solved repair at scale — until now.

We’re excited to support Voitheia as they approach this next major inflection point. 🚀

#LvlUpVentures #PortfolioSpotlight #Biotech #Neuroscience #HealthcareInnovation #Startups #VentureCapital

‍